Artificial Intelligence Driven Imaging Device Tested at AdventHealth

May 18, 2023 | AdventHealth and Adventist World

The real-time test is part of the healthcare organization’s prostate cancer research study.

A new clinical research study, conducted in partnership between CytoVeris Inc. and AdventHealth in central Florida, USA, will investigate the accuracy of using an artificial intelligence (AI)-driven imaging device ) during surgery to improve prostate cancer margin assessment. Called Margin ASSURE, this device should enable more accurate real-time surgical decisions and improve patient outcomes.

The study will focus on CytoVeris’ multispectral imaging capability for intraoperative cancer margin assessment during robot-assisted radical prostatectomy (RARP) and will only include surgeries performed in the United States at AdventHealth Celebration and led by Vipul Patel, Founder and Medical Director of the Global Robotics Institute at AdventHealth Celebration, and his team.

Mr. Patel is globally known for his contributions to the field of robotic-assisted surgery and is one of the most experienced robotic surgeons in the world, having personally performed over 16,000 robotic prostatectomies.

why it matters

According to the American Cancer Society, prostate cancer is the most common cancer in American men, with the exception of skin cancer, and it is estimated that nearly 35,000 people die from this disease each year.

Of the 288,000 men who are diagnosed with prostate cancer each year in the United States, approximately 90,000 undergo RARP-type surgery. Post-surgical positive margin rates are typically in the 20% range and can lead to complications and poorer patient outcomes.

How will the device be used?

During this multi-year study, Dr. Patel will work with CytoVeris to adapt and expand its imaging platform for prostate cancer margin assessment.

“In the operating room, every gesture is crucial. Robotic devices are changing the way we [les chirurgiens] operate with more precision, and therefore better patient outcomes,” Patel said. “This study will attempt to demonstrate MarginASSURE’s ability and suitability for near real-time, label-free cancer detection through the development of advanced tissue characterization technologies that can identify cancerous tissue, assess margins, and identify critical tissue structures. .

The CytoVeris System is based on proprietary multispectral tissue autofluorescence (AF) imaging technology, which analyzes the “optical fingerprint” of tissues based on their intrinsic biomolecular and morphological characteristics, without the use of dyes or dyes. imaging agents.

MarginASSURE, the prostate imaging device, is designed to provide rapid margin assessment of excised prostate specimens and provide the surgeon with actionable data to help guide the surgical steps necessary to optimize patient outcomes and optimize nervous saving.

The project will integrate and correlate preoperative MRI imaging of tumors with MarginASSURE imaging of RARP specimens suspected of extraprostatic/extracapsular spread of cancer in periprostatic soft tissues.

“CytoVeris was founded on the vision that by harnessing advanced optical imaging and artificial intelligence, surgeons will have the ability to visualize cancer when it matters most – in the operating room,” said Alan D Kersey, President and CEO of CytoVeris. “This clinical research study aims to demonstrate and validate our technology in prostate cancer, paving the way to optimizing patient outcomes.”

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top